MCID: EPL164
MIFTS: 70

Epilepsy

Categories: Neuronal diseases, Rare diseases, Genetic diseases

Aliases & Classifications for Epilepsy

MalaCards integrated aliases for Epilepsy:

Name: Epilepsy 12 72 50 51 40 3 41 14 69 59
Epileptic Syndrome 12
Epilepsy Syndrome 12

Classifications:



Summaries for Epilepsy

NINDS : 50 The epilepsies are a spectrum of brain disorders ranging from severe, life-threatening and disabling, to ones that are much more benign. In epilepsy, the normal pattern of neuronal activity becomes disturbed, causing strange sensations, emotions, and behavior or sometimes convulsions, muscle spasms, and loss of consciousness. The epilepsies have many possible causes and there are several types of seizures. Anything that disturbs the normal pattern of neuron activity—from illness to brain damage to abnormal brain development—can lead to seizures. Epilepsy may develop because of an abnormality in brain wiring, an imbalance of nerve signaling chemicals called neurotransmitters, changes in important features of brain cells called channels, or some combination of these and other factors. Having a single seizure as the result of a high fever (called febrile seizure) or head injury does not necessarily mean that a person has epilepsy. Only when a person has had two or more seizures is he or she considered to have epilepsy. A measurement of electrical activity in the brain and brain scans such as magnetic resonance imaging or computed tomography are common diagnostic tests for epilepsy.

MalaCards based summary : Epilepsy, also known as epileptic syndrome, is related to myoclonic epilepsy of unverricht and lundborg and myoclonic epilepsy of lafora, and has symptoms including sleeplessness, non-epileptic convulsion and vertigo/dizziness. An important gene associated with Epilepsy is EPM2A (EPM2A, Laforin Glucan Phosphatase), and among its related pathways/superpathways are Circadian entrainment and Transmission across Chemical Synapses. The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include temporal lobe, brain and testes, and related phenotypes are Resistant to vaccinia virus (VACV-A4L) infection and behavior/neurological

MedlinePlus : 40 Epilepsy is a brain disorder that causes people to have recurring seizures. The seizures happen when clusters of nerve cells, or neurons, in the brain send out the wrong signals. People may have strange sensations and emotions or behave strangely. They may have violent muscle spasms or lose consciousness. Epilepsy has many possible causes, including illness, brain injury, and abnormal brain development. In many cases, the cause is unknown. Doctors use brain scans and other tests to diagnose epilepsy. It is important to start treatment right away. There is no cure for epilepsy, but medicines can control seizures for most people. When medicines are not working well, surgery or implanted devices such as vagus nerve stimulators may help. Special diets can help some children with epilepsy. NIH: National Institute of Neurological Disorders and Stroke

Disease Ontology : 12 A brain disease that is characterized by the occurrance of at least two unprovoked seizures resulting from a persistent epileptogenic abnormality of the brain that is able to spontaneously generate paroxysmal activity and typically manifested by sudden brief episodes of altered or diminished consciousness, involuntary movements, or convulsions.

PubMed Health : 59
About epilepsy: In epilepsy, certain areas of the brain or all areas of the brain are overactive, sending too many signals. This results in seizures, sometimes also referred to as epileptic fits. Epileptic seizures can take different forms. They may cause only a few muscles to twitch, for instance, or they may cause your whole body to convulse (shake uncontrollably) and lead to loss of consciousness.Epilepsy can arise at any age. Some people have their first seizure in childhood, and others have their first seizure in older age. There are usually no physical symptoms in between seizures. But the constant fear of having another seizure may affect your work and private life.Medication can help to prevent seizures and maintain a good quality of life. Unfortunately, medication doesn't always help, though: About 3 out of 10 people still have regular seizures. This makes it particularly difficult for them to live with the condition.

Wikipedia : 72 Epilepsy is a group of neurological disorders characterized by epileptic seizures. Epileptic seizures... more...

Related Diseases for Epilepsy

Diseases in the Epilepsy family:

Benign Familial Infantile Epilepsy

Diseases related to Epilepsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1104)
# Related Disease Score Top Affiliating Genes
1 myoclonic epilepsy of unverricht and lundborg 34.3 CSTB EPM2A
2 myoclonic epilepsy of lafora 34.3 CSTB EPM2A NHLRC1
3 progressive myoclonus epilepsy, lafora type 34.2 EPM2A NHLRC1
4 juvenile absence epilepsy 34.2 CACNA1H EFHC1 GABRA1
5 myoclonic astatic epilepsy 34.1 SCN1A SLC2A1
6 epilepsy, myoclonic juvenile 34.1 CACNB4 EFHC1
7 generalized epilepsy with febrile seizures plus, type 1 34.0 SCN1A SCN1B
8 autosomal dominant nocturnal frontal lobe epilepsy 34.0 CHRNA2 CHRNA4 CHRNB2
9 progressive myoclonus epilepsy 34.0 CSTB EPM2A NHLRC1
10 generalized epilepsy with febrile seizures plus 34.0 EFHC1 GABRA1 GABRG2 SCN1A SCN1B
11 myoclonic epilepsy of infancy 33.9 GABRG2 SCN1A
12 temporal lobe epilepsy 33.9 LGI1 RELN SCN1B
13 febrile infection-related epilepsy syndrome 33.8 POLG SCN1A
14 epilepsy, idiopathic generalized 10 33.8 CACNB4 CHRNA4 CSTB EFHC1 GABRA1 GABRB3
15 epilepsy, nocturnal frontal lobe, 3 33.8 CHRNA4 CHRNB2
16 epilepsy, nocturnal frontal lobe, 1 33.8 CHRNA2 CHRNA4 CHRNB2 GABRG2 SCN1A SCN1B
17 epilepsy, idiopathic generalized 7 33.8 CACNB4 EFHC1
18 epileptic encephalopathy, early infantile, 6 33.7 GABRA1 GABRB3 GABRG2 SCN1A SCN1B
19 autosomal dominant epilepsy with auditory features 33.7 LGI1 RELN
20 epilepsy with generalized tonic-clonic seizures 33.7 CSTB EFHC1 SCN1A
21 myoclonus epilepsy 33.7 CSTB EPM2A NHLRC1
22 autosomal dominant nocturnal frontal lobe epilepsy 2 33.6 CHRNA4 CHRNB2
23 epilepsy, familial temporal lobe, 1 33.6 LGI1 RELN
24 visual epilepsy 33.5 CLN8 NHLRC1 SCN1A SLC2A1
25 early onset absence epilepsy 33.5 CHRNB2 SCN1B SLC2A1
26 focal epilepsy 33.5 CHRNA2 CHRNA4 CHRNB2 GABRG2 GRIN2A LGI1
27 unverricht-lundborg syndrome 33.5 CSTB EFHC1 EPM2A NHLRC1
28 childhood absence epilepsy 33.3 CACNA1H CHRNA4 EFHC1 GABRA1 GABRB3 GABRG2
29 early myoclonic encephalopathy 33.2 CHRNA4 CSTB EPM2A GABRG2 SCN1A SCN1B
30 seizures, benign familial infantile, 3 33.1 CHRNA4 GABRG2 SCN1A SCN1B
31 epilepsy, idiopathic generalized 33.0 CACNA1H CACNB4 CHRNA4 CHRNB2 EFHC1 GABRA1
32 lennox-gastaut syndrome 32.8 GABRA1 GABRB3 SCN1A SLC2A1
33 mental retardation, x-linked, syndromic, hedera type 32.7 GABRA1 LGI1
34 myoclonus 32.6 CSTB EPM2A NHLRC1 SLC2A1
35 febrile seizures 31.5 CHRNA4 GABRG2 SCN1A SCN1B
36 status epilepticus 31.1 LGI1 POLG SCN1A
37 autism spectrum disorder 30.5 GABRB3 GRIN2A RELN SCN1A
38 psychotic disorder 30.0 GABRA1 GABRB3 RELN
39 disease of mental health 29.9 CHRNA4 GRIN2A RELN
40 epilepsy, pyridoxine-dependent 12.3
41 ceroid lipofuscinosis, neuronal, 8, northern epilepsy variant 12.3
42 epilepsy, focal, with speech disorder and with or without mental retardation 12.2
43 benign epilepsy with centrotemporal spikes 12.2
44 centralopathic epilepsy 12.2
45 photosensitive epilepsy 12.2
46 epilepsy-aphasia spectrum 12.2
47 benign familial neonatal epilepsy 12.2
48 epilepsy, familial focal, with variable foci 1 12.2
49 epilepsy, progressive myoclonic 7 12.2
50 epilepsy, progressive myoclonic, 6 12.2

Graphical network of the top 20 diseases related to Epilepsy:



Diseases related to Epilepsy

Symptoms & Phenotypes for Epilepsy

UMLS symptoms related to Epilepsy:


sleeplessness, non-epileptic convulsion, vertigo/dizziness, chronic pain, tremor, syncope, seizures, sciatica, pain, headache, back pain

GenomeRNAi Phenotypes related to Epilepsy according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Resistant to vaccinia virus (VACV-A4L) infection GR00351-A-1 9.23 CACNB4 CSTB EFHC1 GABRA1 GRIN2A NHLRC1

MGI Mouse Phenotypes related to Epilepsy:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.36 EFHC1 EPM2A GABRA1 GABRB3 GABRG2 GRIN2A
2 growth/size/body region MP:0005378 10.21 SCN1A SCN1B SLC2A1 LGI1 POLG RELN
3 mortality/aging MP:0010768 10.17 CACNB4 CHRNA4 CHRNB2 CLN8 EPM2A GABRA1
4 nervous system MP:0003631 10.16 CACNA1H CACNB4 CHRNA2 CHRNA4 CHRNB2 CLN8
5 muscle MP:0005369 9.96 CACNA1H CACNB4 CHRNB2 CSTB EFHC1 EPM2A
6 no phenotypic analysis MP:0003012 9.56 CHRNA4 CSTB GABRA1 GABRB3 NHLRC1 POLG
7 reproductive system MP:0005389 9.28 GABRA1 GABRB3 GABRG2 POLG RELN SCN1A

Drugs & Therapeutics for Epilepsy

PubMedHealth treatment related to Epilepsy: 59

The most suitable kind of treatment for a specific person will depend on the type of epilepsy they have and the course of their disease so far. Epilepsy is usually treated with medication known as anti-epileptic drugs (AEDs). These include various medications from different groups of drugs. If a certain medication doesn’t work when a low dose is used, the dose can be increased. If it still doesn’t work, a medication from a different group of drugs can be tried out or several medications can be used together.Seizures are often one-off events so no treatment is needed at first. People usually only start treatment if they have a second seizure. But certain people, for instance those with a brain disease, are more likely to have further seizures. In those cases it might be a good idea to start treatment after the first seizure. This will greatly depend on the person’s individual situation. It is important to discuss all the options with your doctor.People who decide to take medication usually take it for many years. Some people can try to stop taking medication after a while if they have not had any seizures for several years. Others have to take medication for the rest of their lives.If seizures can’t be prevented with medication, a surgical procedure may be considered. The options include:Brain surgery: If someone has partial seizures and it is clear which part of the brain is triggering them, that part of the brain can be surgically removed. But this is not always possible.Vagus nerve stimulation: In this procedure, a pacemaker-like device is implanted under the skin of your chest, where it produces electrical signals. It is connected to the vagus nerve in your neck and is meant to prevent the nerve cells from being too active.The treatment is overseen by a neurologist. Children and teenagers with epilepsy will see a pediatric neurologist. Some of the diagnostic tests and treatments are often carried out in a hospital. There are outpatient facilities and clinics that specialize in treatments for people with epilepsy (e.g. epilepsy centers, specialized hospital departments or doctors’ practices). These are particularly suitable if you have a specific problem, if the diagnosis is not clear, or if you keep on having seizures despite treatment.When people with epilepsy have seizures they do not usually need treatment. The most important thing that helpers can do is stay calm and prevent injury. If the seizure lasts longer than five minutes or if several seizures occur within a short space of time, the emergency services should be informed (e.g. by calling 112 in Germany and most European countries, or 911 in the U.S.). Severe epileptic seizures may require a hospital stay.

Drugs for Epilepsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 551)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
3
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 97240-79-4 5284627
4
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
5
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
6
Acetazolamide Approved, Vet_approved Phase 4,Phase 2,Phase 3 59-66-5 1986
7
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 298-46-4 2554
8
Clobazam Approved, Illicit Phase 4,Phase 3,Phase 2 22316-47-8 2789
9
Clonazepam Approved, Illicit Phase 4,Phase 3,Phase 2 1622-61-3 2802
10
Ethosuximide Approved Phase 4,Phase 3 77-67-8 3291
11
Felbamate Approved Phase 4 25451-15-4 3331
12
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 60142-96-3 3446
13
Nitrazepam Approved Phase 4,Phase 2 146-22-5 4506
14
Oxcarbazepine Approved Phase 4,Phase 3,Phase 2,Phase 1 28721-07-5 34312
15
Phenobarbital Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-06-6 4763
16
Phenytoin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-41-0 1775
17
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 148553-50-8 5486971
18
Tiagabine Approved, Investigational Phase 4,Phase 1 115103-54-3 60648
19
Vigabatrin Approved Phase 4,Phase 3,Phase 2 68506-86-5, 60643-86-9 5665
20
Zonisamide Approved, Investigational Phase 4,Phase 3 68291-97-4 5734
21 Piracetam Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 7491-74-9
22
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 59467-70-8 4192
23
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 2078-54-8 4943
24
Lacosamide Approved Phase 4,Phase 3,Phase 2,Phase 1 860352-01-8, 175481-36-4 219078
25
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
26
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 56-12-2 119
27
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
28
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
29
Eslicarbazepine acetate Approved Phase 4,Phase 3,Phase 2,Phase 1 236395-14-5, 75970-99-9 123618
30
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
31
Acetylcholine Approved Phase 4,Phase 2 51-84-3 187
32
Lorazepam Approved Phase 4,Phase 3,Phase 2,Phase 1 846-49-1 3958
33
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 159351-69-6 6442177
34
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 22916-47-8 4189
35
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 53123-88-9 46835353 6436030 5284616
36
Amitriptyline Approved Phase 4,Phase 3 50-48-6 2160
37
Tranexamic Acid Approved Phase 4,Phase 3 1197-18-8 5526
38
Methylphenidate Approved, Investigational Phase 4 20748-11-2, 113-45-1 4158
39
Levonorgestrel Approved, Investigational Phase 4,Phase 1 797-63-7, 17489-40-6 13109
40
Citalopram Approved Phase 4 59729-33-8 2771
41
Clevidipine Approved, Investigational Phase 4 167221-71-8
42
Hydralazine Approved Phase 4 86-54-4 3637
43
Labetalol Approved Phase 4 36894-69-6 3869
44
Sertraline Approved Phase 4,Phase 3 79617-96-2 68617
45
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
46
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
47
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
48
Fosphenytoin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 93390-81-9 56339
49
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 1 76631-46-4, 113775-47-6 5311068 56032 68602
50
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774

Interventional clinical trials:

(show top 50) (show all 1598)

# Name Status NCT ID Phase Drugs
1 The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy Unknown status NCT00647322 Phase 4
2 Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy Unknown status NCT00454935 Phase 4
3 Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody Unknown status NCT02695797 Phase 4 Prednisolone
4 Topiramate Treatment for Patients With Epilepsy and Learning Disability : A Prospective Observational Study Unknown status NCT00956696 Phase 4 topiramate
5 Hormone Profiles in Adults With Newly Diagnosed Epilepsy Unknown status NCT00137709 Phase 4 Sodium valproate;Lamotrigine
6 Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy Unknown status NCT00552526 Phase 4 Antiepileptic drug (AED)
7 Study to Improve the Treatment of Epilepsy (SITE) Unknown status NCT00133081 Phase 4 All registered antiepileptic drugs
8 BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients Unknown status NCT02404168 Phase 4 lamotrigine (brand Lamictal);lamotrigine (generic Teva)
9 Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote Unknown status NCT00312676 Phase 4
10 A Trial of Generic Substitution of Antiepileptic Drugs Unknown status NCT02429596 Phase 4 Experimental
11 Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients Unknown status NCT00132223 Phase 4 Contrast agent
12 Levetiracetam Treatment of Children With Subclinical Sleep-Activated Epileptiform Activity (SSEA) Unknown status NCT00393614 Phase 4 levetiracetam
13 Melatonin Versus Placebo in the Lennox-Gastaut Syndrome: Neurophysiological and Neuropsychological Effects Unknown status NCT01370486 Phase 4 melatonin;placebo
14 Comparison of Oral 30 % Dextrose and iv Midazolam Sedation During MRI in Neonates Unknown status NCT02645279 Phase 4 IV midazolam
15 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
16 Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases Unknown status NCT00796380 Phase 4 Xingnaojing
17 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
18 Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old. Unknown status NCT01478035 Phase 4 Phenytoin;placebo
19 Lamotrigine Cognitive Function Study in Adult Untreated Epilepsies Completed NCT00896987 Phase 4 lamotrigine (Lamictal);Carbamazepine (Tegretol)
20 Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study) Completed NCT01733394 Phase 4 Lamotrigine Generic "A" Lamotrigine Generic "B" Lamotrigine "Brand";lamotrigine
21 Study on Migraine and Headache in Epileptic Patients Completed NCT00642564 Phase 4
22 Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design Completed NCT01713777 Phase 4 Lamotrigine Generic "A";Lamotrigine generic "B"
23 Standardized Educational Plan for Epilepsy Patients With Comorbidities Completed NCT01804322 Phase 4
24 Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study Completed NCT02100644 Phase 4 Lamotrigine tablets 25/100 mg
25 Cognitive and Behavioral Effects of Lacosamide Completed NCT01175954 Phase 4 Lacosamide;Lacosamide
26 Methylphenidate Treatment of Attention Deficits in Epilepsy Completed NCT02178995 Phase 4 Methylphenidate
27 RCT of the Efficacy of the Ketogenic Diet in the Treatment of Epilepsy Completed NCT00564915 Phase 4
28 An Observational Study to Evaluate Long-term Retention Rate of Topiramate in Participants With Epilepsy Completed NCT01682681 Phase 4 Topiramate
29 Heart Rate Changes During Normal Activity, Exercise, and Seizures in Subjects With Epilepsy Completed NCT01214707 Phase 4
30 Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users Completed NCT02362373 Phase 4 levonorgestrel IUS
31 Levetiracetam for Benign Rolandic Epilepsy Completed NCT00181116 Phase 4 Levetiracetam
32 Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy: Completed NCT00356018 Phase 4
33 Safety and Efficacy of Topamax Versus Carbamazepine in Benign Rolandic Epilepsy Completed NCT00216567 Phase 4 topamax
34 Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy Completed NCT01140867 Phase 4 zonisamide
35 A Study to Assess Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy Completed NCT01689649 Phase 4 Topiramate
36 Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy Completed NCT01190098 Phase 4 Lacosamide;Placebo
37 Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy. Completed NCT00245713 Phase 4 levetiracetam
38 Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy Completed NCT00043914 Phase 4 lamotrigine
39 Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA) Completed NCT00302991 Phase 4
40 Open Label Study of Zonisamide in the Treatment of Epilepsy in Patients With Mental Retardation Completed NCT00298818 Phase 4
41 Effect of Three Different Doses of Oral Cholecalciferol on 25-Hydroxyvitamin D Changes Among Epilepsy Patients With Hypovitaminosis D Completed NCT02890823 Phase 4 Cholecalciferol
42 Non-Interventional Study With LYRICA (Pregabalin) In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency Completed NCT00684424 Phase 4
43 S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy Completed NCT00630968 Phase 4 Levetiracetam (Keppra)
44 Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy Completed NCT01498822 Phase 4 Levetiracetam;Oxcarbazepine
45 Study of Valproate in Young Patients Suffering From Epilepsy Completed NCT00385411 Phase 4 valproate microgranules
46 A Cross-sectional Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Female Participants With Epilepsy Completed NCT01030094 Phase 4 Topiramate;Carbamazepine;Valproic acid;Normal control
47 Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy Completed NCT00160654 Phase 4 Levetiracetam
48 Switchability Study Between Brand and Generic Topiramate Completed NCT02113787 Phase 4
49 Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures Completed NCT00955357 Phase 4 Lacosamide
50 Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy Completed NCT00323947 Phase 4 Extended Release Methylphenidate (OROS-Methylphenidate)

Search NIH Clinical Center for Epilepsy

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: epilepsy

Genetic Tests for Epilepsy

Anatomical Context for Epilepsy

MalaCards organs/tissues related to Epilepsy:

38
Temporal Lobe, Brain, Testes, Cortex, Bone, Heart, Thalamus

Publications for Epilepsy

Articles related to Epilepsy:

(show top 50) (show all 6807)
# Title Authors Year
1
KANSL1 variation is not a major contributing factor in self-limited focal epilepsy syndromes of childhood. ( 29352316 )
2018
2
Refractory focal epilepsy in a paediatric patient with primary familial brain calcification. ( 29448117 )
2018
3
Vagal nerve stimulation for medically refractory epilepsy in Angelman syndrome: a series of three cases. ( 29350262 )
2018
4
Evidence on the efficacy of primary radiosurgery or stereotactic radiotherapy for drug-resistant non-neoplastic focal epilepsy in adults: A systematic review. ( 29414140 )
2018
5
GRIN2A mutations in epilepsy-aphasia spectrum disorders. ( 29056244 )
2018
6
Development of Neuromyelitis Optica Spectrum Disorder and Spinal Arachnoid Cysts in a Patient With Intractable Epilepsy. ( 29379967 )
2018
7
A de novo mutation in RPL10 causes a rare X-linked ribosomopathy characterized by syndromic intellectual disability and epilepsy: A new case and review of the literature. ( 29066376 )
2018
8
Progressive topological disorganization of brain network in focal epilepsy. ( 29344935 )
2018
9
Cognitive functioning in dyskinetic cerebral palsy: Its relation to motor function, communication and epilepsy. ( 29108712 )
2018
10
Oxidative stress in patients with refractory temporal lobe epilepsy and mesial temporal sclerosis: Possible association with major depressive disorder? ( 29414551 )
2018
11
SRR intronic variation inhibits expression of its neighbouring SMG6 gene and protects against temporal lobe epilepsy. ( 29363864 )
2018
12
Onchocerciasis associated epilepsy: An important neglected public health problem. ( 29325732 )
2018
13
Familial Cortical Myoclonic Tremor and Epilepsy, an Enigmatic Disorder: From Phenotypes to Pathophysiology and Genetics. A Systematic Review. ( 29416935 )
2018
14
Thirty-day outcome in pediatric epilepsy surgery. ( 29445917 )
2018
15
Losigamone add-on therapy for focal epilepsy. ( 29355908 )
2018
16
Modeling pathogenesis and treatment response in childhood absence epilepsy. ( 29265352 )
2018
17
Indirect comparison of third-generation antiepileptic drugs as adjunctive treatment for uncontrolled focal epilepsy. ( 29197667 )
2018
18
Attention profiles in childhood absence epilepsy compared with attention-deficit/hyperactivity disorder. ( 28992996 )
2018
19
Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. ( 29399791 )
2018
20
Spinal muscular atrophy with progressive myoclonic epilepsy linked to mutations in ASAH1. ( 29169047 )
2018
21
The relationship between structural MRI, FDG-PET, and memory in temporal lobe epilepsy: Preliminary results. ( 29414560 )
2018
22
Utility of additional dedicated high-resolution 3T MRI in children with medically refractory focal epilepsy. ( 29398181 )
2018
23
Febrile infection-related epilepsy syndrome (FIRES) with super-refractory status epilepticus revealing autoimmune encephalitis due to GABA<sub>A</sub>R antibodies. ( 29203057 )
2018
24
Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic review. ( 29428899 )
2018
25
The oxymoron of image-guided resection in 3a8^T MRI-negative extratemporal epilepsy: Technique and postoperative results. ( 29358107 )
2018
26
Differential patterns of dynamic functional connectivity variability of striato-cortical circuitry in children with benign epilepsy with centrotemporal spikes. ( 29206330 )
2018
27
Childhood-onset generalized epilepsy in Bainbridge-Ropers syndrome. ( 29367179 )
2018
28
Stereotactic Laser Amygdalohippocampotomy for Mesial Temporal Lobe Epilepsy. ( 29420840 )
2018
29
Integrity of the corpus callosum in patients with periventricular nodular heterotopia related epilepsy by FLNA mutation. ( 29062687 )
2018
30
Antiepileptic drug reduction and increased risk of stimulation-evoked focal to bilateral tonic-clonic seizure during cortical stimulation in patients with focal epilepsy. ( 29414538 )
2018
31
CNTNAP2 mutations and autosomal dominant epilepsy with auditory features. ( 29179159 )
2018
32
Predictive value of preoperative statistical parametric mapping of regional glucose metabolism in mesial temporal lobe epilepsy with hippocampal sclerosis. ( 29247965 )
2018
33
Allocation of Treatment Responsibility in Adolescents With Epilepsy: Associations With Cognitive Skills and Medication Adherence. ( 29447360 )
2018
34
A novel mutation in LAMC3 associated with generalized polymicrogyria of the cortex and epilepsy. ( 29247375 )
2018
35
Effectiveness of a multicomponent self-management intervention for adults with epilepsy (ZMILE study): A randomized controlled trial. ( 29449140 )
2018
36
High-Throughput Data of Circular RNA Profiles in Human Temporal Cortex Tissue Reveals Novel Insights into Temporal Lobe Epilepsy. ( 29428937 )
2018
37
A bidirectional association between cognitive ability in young adulthood and epilepsy: a population-based cohort study. ( 29452371 )
2018
38
Impaired spatial pattern separation performance in temporal lobe epilepsy is associated with visuospatial memory deficits and hippocampal volume loss. ( 29428769 )
2018
39
Effect of epilepsy on autism symptoms in Angelman syndrome. ( 29340132 )
2018
40
SPECT perfusion changes during ictal automatisms with preserved responsiveness in patients with right temporal lobe epilepsy. ( 29396356 )
2018
41
Reflex epilepsy: triggers and management strategies. ( 29403278 )
2018
42
Alterations of theta oscillation in executive control in temporal lobe epilepsy patients. ( 29358157 )
2018
43
Laser ablation is effective for temporal lobe epilepsy with and without mesial temporal sclerosis if hippocampal seizure onsets are localized by stereoelectroencephalography. ( 29392715 )
2018
44
Treating Immune-Related Epilepsy. ( 29445957 )
2018
45
The ketogenic diet is effective for refractory epilepsy associated with acquired structural epileptic encephalopathy. ( 29451698 )
2018
46
Somatosensory reflex epilepsy: simultaneous video-EEG monitoring and surface EMG. ( 29444763 )
2018
47
Epilepsy in Children After Pandemic Influenza Vaccination. ( 29449342 )
2018
48
Follow-Up of Peripheral IL-1I^ and IL-6 and Relation with Apoptotic Death in Drug-Resistant Temporal Lobe Epilepsy Patients Submitted to Surgery. ( 29401729 )
2018
49
Behavioral interventions as a treatment for epilepsy: A multicenter randomized controlled trial. ( 29444968 )
2018
50
Long-Term Electroclinical and Employment Follow up in Temporal Lobe Epilepsy Surgery. A Cuban Comprehensive Epilepsy Surgery Program. ( 29389846 )
2018